Two positive Phase III readouts for Biohaven's CGRP-blocking migraine drug

Connecticut, USA-based neurology specialist Biohaven Pharmaceutical (NYSE: BHVN) has announced positive top-line data from two Phase III trials of the CGRP receptor antagonist rimegepant.

The oral therapy is being tested as a treatment for acute migraine. In each trial, rimegepant met the co-primary efficacy endpoints of superiority to placebo, at two hours post-dose, on pain freedom and freedom from the most bothersome symptom (MBS), a commonly used measure.

Chief executive Vlad Coric said the data “show that a single, oral dose of rimegepant has the potential to be an effective and safe acute treatment for migraine, addressing both pain and most bothersome symptoms without the need for repeat dosing or rescue medicines.”